COLUMBUS, Ohio — Neucore Bio, an early-stage biotechnology company advancing the therapeutic potential of non-viral, engineered exosomes, today announced the receipt of a $350,000 STTR Phase I grant from the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH) to evaluate the Company’s targeted...
treatment News
SAN DIEGO, CA — Neuralace Medical, Inc., an innovator in pain management technology, today proudly announces the FDA clearance of its groundbreaking product, Axon Therapy (mPNS), for the treatment of chronic Painful Diabetic Neuropathy (PDN). This landmark approval marks the first-ever FDA clearance of a non-invasive, magnetic peripheral nerve stimulation (mPNS)...
GAITHERSBURG, Md. — Neuraly, Inc., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating pegsebrenatide (NLY01), Neuraly’s long-acting GLP1 receptor agonist, for the potential treatment of patients with multiple sclerosis (MS). Multiple sclerosis...
WAYNE, Pa. — Neuraptive Therapeutics Inc., a leader in innovative medical solutions, is pleased to announce that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its fusogen contained in the NTX-001 treatment kit. This designation marks a significant milestone in developing NTX-001, a...
MELBOURNE, Australia — Neuren Pharmaceuticals Limited today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics....
MONTREAL, Québec — Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day. Neurenati, a Québec-based biotech company, focuses on the development of various rare diseases therapies, including pediatric conditions. Combined with the...
SCHLIEREN, Switzerland – AL-S Pharma AG, a biotech company jointly founded by Neurimmune and TVM Capital Life Science, announced today enrollment of the first patient in a multicenter, placebo-controlled Phase 2 clinical trial to evaluate AP-101 in patients with amyotrophic lateral sclerosis (ALS). AP-101 is a human antibody directed against misfolded...
Highlights: Last Open-Label Extension (OLE) study patient successfully completes 12-month treatment period Treatment with NUZ-001 continues to be well-tolerated and shows promising results in extending the life expectancy of patients with MND/ALS Key findings compared to untreated matched controls from the PRO-ACT Historical Database were: NUZ-001 significantly increased survival (χ2=14.1, p=0.00017)...
MELBOURNE Australia — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon’s lead...
MELBOURNE, Australia — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), is pleased to announce that the Bellberry Human Research Ethics Committee (HREC) has approved the Company’s Phase 1 formulation study supporting development of the NUZ-001 oral liquid formulation, representing a further milestone in the development...